Healthcare Industry News: phenylketonuria
News Release - September 3, 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate AffairsSAN RAFAEL, Calif., Sept. 3, 2013 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (BMRN) today announced the appointment of Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs. Mr. Ranieri will start on September 4, 2013.
"We are very pleased to welcome Rich to BioMarin. He brings a wealth of human resources experience to the company as we continue our rapid growth. He has the depth and breadth of global experience that BioMarin needs as it scales its operations to meet its expanding business," said Jean-Jacques Bienaime, Chief Executive Officer. "As an experienced senior level human resources executive in the biopharma industry, Rich is extremely well-qualified to fill this leadership role and will be an instrumental member of the organization."
Mr. Ranieri most recently served as Executive Vice President, Human Resources at Dendreon Corporation from 2010 to 2013 where he was responsible for all aspects of human resources and oversaw the expansion of the workforce from 150 to 2,000 employees. Prior to Dendreon, Mr. Ranieri was the Executive Vice President, Human Resounces & Administration at Sepracor, Inc. where he managed and directed Human Resources, Corporate Services, Facilities and Communications. Earlier in his career, Mr. Ranieri served in executive positions at Neurocrine Biosciences, Inc., Genencor International and Smithkline Beecham. He received a BA from Villanova University and an MA in organizational development from Rider University.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(R) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include Vimizim (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase III clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
Vimizim(TM) is our trademark, and BioMarin(R), Naglazyme(R), Kuvan(R), Firdapse(R) are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.
Source: BioMarin Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBioMarin Receives FDA Approval for VOXZOGO(TM) (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
European Commission Approves BioMarin's VOXZOGO(R) (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close